[EN] CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] [FR] THIAZOLES SUBSTITUÉS PAR CARBOXAMIDE OU SULFONAMIDE ET DÉRIVÉS APPARENTÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR NUCLÉAIRE ORPHELIN ROR[GAMMA]
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
申请人:——
公开号:US20040077605A1
公开(公告)日:2004-04-22
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
申请人:Salvati E. Mark
公开号:US20050119228A1
公开(公告)日:2005-06-02
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
The invention relates to novel compounds of the formula (I)
in which Z, Y, A
1
, A
2
, A
3
, A
4
, X, R
7
, R
8
and R
9
have the meanings mentioned above,
and processes and intermediates for the preparation thereof, and their use for controlling animal pests, in particular insects.
[EN] FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION<br/>[FR] COMPOSES DE SUCCINIMIDE HETEROCYCLIQUES FUSIONNES ET LEURS ANALOGUES, MODULATEURS DE LA FONCTION DE RECEPTEUR HORMONAL NUCLEAIRE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2002024702A1
公开(公告)日:2002-03-28
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
申请人:Salvati E. Mark
公开号:US20050272799A1
公开(公告)日:2005-12-08
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.